However, more than 90% of glioblastomas recur within 24 months after Stupp standard procedures, and approximately 50% of glioblastomas classified as O6-methylguanine-DNA methyltransferase (MGMT) unmethylation, which are resistant to TMZ therapy [3,4], result in poor prognosis of patients with recurrent GBM. The gene discussed is MGMT; the disease is glioblastoma.